摘要
恶性肿瘤的发生发展与血管生成息息相关,现已成为抗肿瘤治疗的新靶点。阿帕替尼是新型小分子抗血管生成抑制剂,主要通过结合血管内皮生长因子受体2抑制肿瘤新生血管生成,发挥理想的抗肿瘤功效。阿帕替尼一直被用于晚期胃癌的治疗,显示出理想的抗肿瘤效应与良好的耐受性。目前,阿帕替尼在恶性肿瘤抗血管生成方面的应用价值越来越高,已逐渐被临床用于晚期肺癌的治疗,并取得良好效果,未来将为晚期肺癌的治疗提供新选择。
Angiogenesis is closely related to the occurrence and development of malignant tumors,and it has become a new target for anti-tumor therapy.Apatinib is a novel small molecule anti-angiogenic inhibitor,which can combine with vascular endothelial growth factor receptor 2 to inhibit tumor neovascularization,thus exerting ideal anti-tumor effects.Apatinib has been used in the treatment of advanced gastric cancer and has shown ideal anti-tumor effect and good tolerance.At present,the application value of apatinib in anti-angiogenesis of malignant tumors is getting higher,and it has been gradually applied in the clinical treatment of advanced lung cancer,and has achieved good results.In the future,it will provide new options for the treatment of advanced lung cancer.
作者
陈静
侯海龙
CHEN Jing;HOU Hailong(Department of Radiotherapy,Meihekou Central Hospital,Meihekou 135000,China;Department of Respiratory,Meihekou Central Hospital,Meihekou 135000,China)
出处
《医学综述》
2020年第13期2580-2583,2589,共5页
Medical Recapitulate
